View More Recent Stories
-
Citi Starts Structure Therapeutics (GPCR) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Structure Therapeutics (GPCR)
-
Citizens JMP Reiterates Market Outperform Rating on Structure Therapeutics (GPCR)
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
-
Cantor Fitzgerald says more options, newer targets will expand obesity market
-
Will Pfizer step into the obesity ring? Wolfe Research answers
-
Structure Therapeutics (GPCR) PT Lowered to $60 at Leerink Partners
-
Structure Therapeutics (GPCR) PT Lowered to $87 at Citizens JMP
-
JMP Securities Biotechnology Overview
-
Stifel Starts Structure Therapeutics (GPCR) at Buy, PT $50
-
Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies
-
Viking Therapeutics (VKTX), Others Gain After Novo Nordisk (NVO) Data Falls Short of Expectations
-
H.C. Wainwright Reiterates Buy Rating on Structure Therapeutics (GPCR)
-
Piper Sandler on Structure Therapeutics (GPCR): 'We Continue to See GPCR as One of Our Best 2025 Ideas'
-
Structure Therapeutics (GPCR) Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
BMO Capital Reiterates Outperform Rating on Structure Therapeutics (GPCR)
-
Morgan Stanley Starts Structure Therapeutics (GPCR) at Overweight
-
Structure Therapeutics (GPCR) Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
-
Structure Therapeutics (GPCR) Appoints Blai Coll as Chief Medical Officer, Ashley Hall as Chief Development Officer
-
Piper Sandler Reiterates Overweight Rating on Structure Therapeutics (GPCR)
-
Here's the list of biotech stocks that have key data catalysts in 2025
-
BMO Capital Reiterates Outperform Rating on Structure Therapeutics (GPCR)
